Connecticut is currently home to 1245 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Quality of Life in Pediatric Patients with Acute Lymphoblastic Leukemia Receiving Maintenance Chemotherapy
NCT03132948
Recruiting
The purpose of the study is to evaluate the impact of exercise on physical activity levels and quality of life in children with acute lymphoblastic leukemia (ALL) receiving maintenance chemotherapy.
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
03/17/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Quality of Life
Register for Updates
Stem Cell Ophthalmology Treatment Study II
NCT03011541
Recruiting
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: MD Stem Cells, Westport, Connecticut
Conditions: Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Register for Updates
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
NCT06821061
Recruiting
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Clinical Research Consulting, Milford, Connecticut
Conditions: Influenza, COVID-19 (Coronavirus Disease 2019)
Register for Updates
Efficacy of Guselkumab in Treating Hailey Hailey Disease
NCT06651489
Recruiting
Hailey-Hailey disease (HHD) is a debilitating genetic skin disorder, affecting mainly body folds with erythema and painful erosions and blisters. Histopathological findings include epidermal hyperplasia, suprabasilar clefting, dyskeratosis and acantholysis of keratinocytes. A final diagnosis of HHD is usually confirmed based on clinical and histopathological findings in line with genetic testing. Several treatment options have been proposed for this chronic and disabling disorder, however, ther... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/14/2025
Locations: Church Street Research Unit, Yale Center for Clinical Investigation, New Haven, Connecticut
Conditions: Hailey Hailey Disease
Register for Updates
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
NCT05989347
Recruiting
The primary objective of the study is to assess metabolic plasma markers of insulin resistance in patients with early-stage HER2-negative breast cancers receiving dapagliflozin concomitant with neoadjuvant therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Yale Cancer Center Smilow Cancer Hospital, New Haven, Connecticut
Conditions: Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
Register for Updates
Written Exposure Therapy for Veterans With SUD and PTSD
NCT05327504
Recruiting
The proposed project will evaluate the efficacy of written exposure therapy (WET) among Veterans engaged in substance use disorder (SUD) treatment, who present with co-occurring posttraumatic stress disorder (PTSD). While SUD treatment programs traditionally do not address PTSD, effective trauma treatments have been used successfully among those with substance use comorbidities. WET is a brief trauma-focused intervention shown to effectively treat PTSD. In a recent acceptability and feasibility... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Conditions: Substance Use Disorders, Posttraumatic Stress Disorder
Register for Updates
The DISCOVER INOCA Prospective Multi-center Registry
NCT05288361
Recruiting
The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Ischemia and no Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Register for Updates
A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer
NCT05226507
Recruiting
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Yale Gynecologic Oncology, New Haven, Connecticut
Conditions: Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
Register for Updates
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
NCT04422912
Recruiting
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Pemphigus Vulgaris
Register for Updates
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
NCT04068194
Recruiting
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
A Study of GSK5764227 in Participants With Advanced Solid Tumors
NCT06551142
Recruiting
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: GSK Investigational Site, New Haven, Connecticut
Conditions: Neoplasms
Register for Updates
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
NCT05908084
Recruiting
The goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the ATEV and AVF groups over 12 months in patients with end-stage renal disease (ESRD) needing hemodialysis (HD). Participants will be stratified by location of the vascular access (forearm versus upper arm) and by type of AVF creation procedure planned by the surgeon at randomization (1-stage AVF versus 2-stage AVF). The comparator is... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: End Stage Renal Disease (ESRD)
Register for Updates